Literature DB >> 20837480

RANKL up-regulates brain-type creatine kinase via poly(ADP-ribose) polymerase-1 during osteoclastogenesis.

Jianfeng Chen1, Yong Sun, Xia Mao, Qizhan Liu, Hui Wu, Yabing Chen.   

Abstract

Receptor activator of nuclear factor κB ligand (RANKL) is the key regulator for osteoclast formation and function. During osteoclastogenesis, RANKL-stimulated signals differentially modulate expression of a large number of proteins. Using proteomics approaches, we identified that brain-type cytoplasmic creatine kinase (Ckb) was greatly induced in mature osteoclasts. Ckb has been shown to contribute to osteoclast function. However, the mechanisms of Ckb regulation and the contribution of other isoforms of creatine kinase during RANKL-induced osteoclastogenesis are unknown. We found that Ckb was the predominant isoform of creatine kinase during osteoclastogenesis. Real-time PCR confirmed that RANKL induced ckb mRNA expression by over 40-fold in primary mouse bone marrow macrophages and Raw 264.7 cells. The RANKL-responsive region was identified within the -0.4- to -0.2-kb 5'-flanking region of the ckb gene. Affinity binding purification followed by mass spectrometry analysis revealed that poly(ADP-ribose) polymerase-1 (PARP-1) bound to the -0.4/-0.2-kb fragment that negatively regulated expression of ckb in response to RANKL stimulation. Electrophoretic mobility shift assays with PARP-1-specific antibody located the binding site of PARP-1 to the TTCCCA consensus sequence. The expression of PARP-1 was reduced during RANKL-induced osteoclastogenesis, concurrently with increased expression of Ckb. Consistently, knockdown of PARP-1 by lentivirus-delivered shRNA enhanced ckb mRNA expression. The activity of PARP-1 was determined to be required for its inhibitory effect on the ckb expression. In summary, we have demonstrated that PARP-1 is a negative regulator of the ckb expression. Down-regulation of PARP-1 is responsible for the up-regulation of ckb during RANKL-induced osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837480      PMCID: PMC2978559          DOI: 10.1074/jbc.M110.157743

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification.

Authors:  Y P Li; W Chen; Y Liang; E Li; P Stashenko
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

Review 2.  ATPase pumps in osteoclasts and osteoblasts.

Authors:  Martin J O Francis; Rita L Lees; Elisa Trujillo; Pablo Martín-Vasallo; Johan N M Heersche; Ali Mobasheri
Journal:  Int J Biochem Cell Biol       Date:  2002-05       Impact factor: 5.085

3.  Sequence-specific binding of poly(ADP-ribose) polymerase-1 to the human T cell leukemia virus type-I tax responsive element.

Authors:  Zhan Zhang; Ellen F Hildebrandt; Cynthia M Simbulan-Rosenthal; Mark G Anderson
Journal:  Virology       Date:  2002-04-25       Impact factor: 3.616

4.  Transcriptional activation of rat creatine kinase B by 17beta-estradiol in MCF-7 cells involves an estrogen responsive element and GC-rich sites.

Authors:  F Wang; I Samudio; S Safe
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

5.  Creatine kinase, an ATP-generating enzyme, is required for thrombin receptor signaling to the cytoskeleton.

Authors:  V B Mahajan; K S Pai; A Lau; D D Cunningham
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

6.  A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression.

Authors:  C Nirodi; S NagDas; S P Gygi; G Olson; R Aebersold; A Richmond
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

7.  Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene.

Authors:  Y Chen; J J Billadello; D J Schneider
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

Review 8.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility.

Authors:  Carolina R Jost; Catharina E E M Van Der Zee; Henricus J A In 't Zandt; Frank Oerlemans; Michel Verheij; Femke Streijger; Jack Fransen; Arend Heerschap; Alexander R Cools; Bé Wieringa
Journal:  Eur J Neurosci       Date:  2002-05       Impact factor: 3.386

10.  Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis.

Authors:  A Frattini; P J Orchard; C Sobacchi; S Giliani; M Abinun; J P Mattsson; D J Keeling; A K Andersson; P Wallbrandt; L Zecca; L D Notarangelo; P Vezzoni; A Villa
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

View more
  11 in total

1.  NLRP3 mediates osteolysis through inflammation-dependent and -independent mechanisms.

Authors:  Chao Qu; Sheri L Bonar; Cynthia L Hickman-Brecks; Samer Abu-Amer; Matthew D McGeough; Carla A Peña; Lori Broderick; Chang Yang; Susan K Grimston; Jacqueline Kading; Yousef Abu-Amer; Deborah V Novack; Hal M Hoffman; Roberto Civitelli; Gabriel Mbalaviele
Journal:  FASEB J       Date:  2014-12-04       Impact factor: 5.191

2.  Serum creatine kinase isoenzymes in children with osteogenesis imperfecta.

Authors:  P D'Eufemia; R Finocchiaro; A Zambrano; V Lodato; L Celli; S Finocchiaro; P Persiani; A Turchetti; M Celli
Journal:  Osteoporos Int       Date:  2016-08-25       Impact factor: 4.507

3.  Induction of creatine kinase release from cultured osteoclasts via the pharmacological action of aminobisphosphonates.

Authors:  Makoto Tanaka; Hiroshi Mori; Ryoji Kayasuga; Kazuhito Kawabata
Journal:  Springerplus       Date:  2015-02-03

4.  Poly-ADP-ribosylation-mediated degradation of ARTD1 by the NLRP3 inflammasome is a prerequisite for osteoclast maturation.

Authors:  C Wang; C Qu; Y Alippe; S L Bonar; R Civitelli; Y Abu-Amer; M O Hottiger; G Mbalaviele
Journal:  Cell Death Dis       Date:  2016-03-24       Impact factor: 8.469

5.  Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.

Authors:  Kenta Mukaihara; Yoshiyuki Suehara; Shinji Kohsaka; Keisuke Akaike; Yu Tanabe; Daisuke Kubota; Midori Ishii; Tsutomu Fujimura; Saiko Kazuno; Taketo Okubo; Tatsuya Takagi; Takashi Yao; Kazuo Kaneko; Tsuyoshi Saito
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

Review 6.  Role of APD-Ribosylation in Bone Health and Disease.

Authors:  Chun Wang; Gabriel Mbalaviele
Journal:  Cells       Date:  2019-10-05       Impact factor: 6.600

7.  An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Authors:  Erica M Stringer-Reasor; Jori E May; Eva Olariu; Valerie Caterinicchia; Yufeng Li; Dongquan Chen; Deborah L Della Manna; Gabrielle B Rocque; Christos Vaklavas; Carla I Falkson; Lisle M Nabell; Edward P Acosta; Andres Forero-Torres; Eddy S Yang
Journal:  Breast Cancer Res       Date:  2021-03-04       Impact factor: 6.466

8.  PARP1 Hinders Histone H2B Occupancy at the NFATc1 Promoter to Restrain Osteoclast Differentiation.

Authors:  Chun Wang; Jianqiu Xiao; Kathrin Nowak; Kapila Gunasekera; Yael Alippe; Sheree Speckman; Tong Yang; Dustin Kress; Yousef Abu-Amer; Michael O Hottiger; Gabriel Mbalaviele
Journal:  J Bone Miner Res       Date:  2020-01-07       Impact factor: 6.741

9.  CD109 plays a role in osteoclastogenesis.

Authors:  Yongqiang Wang; Maayan Inger; Hongwei Jiang; Howard Tenenbaum; Michael Glogauer
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).

Authors:  Giovanni Luca Gravina; Monica Tortoreto; Andrea Mancini; Alessandro Addis; Ernesto Di Cesare; Andrea Lenzi; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Nadia Zaffaroni; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-10-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.